focus -WSS

focus

author：Wikipedia 2025-08-26 10:55:34 - browse：788

The Food and Drug Administration on Friday approved the world’s first medicine based on CRISPR gene-editing technology, a groundbreaking treatment for sickle cell disease that delivers a potential cure for people born with the chronic and life-shortening blood disorder.

The new medicine, called Casgevy, is made by Vertex Pharmaceuticals and CRISPR Therapeutics. Its authorization is a scientific triumph for the technology that can efficiently and precisely repair DNA mutations — ushering in a new era of genetic medicines for inherited diseases.

In a clinical trial, Casgevy was shown to eliminate recurrent episodes of debilitating pain caused by sickle cell, which afflicts approximately 100,000 people in the U.S., a vast majority of whom are Black. The therapy, whose scientific name is exa-cel, is described as a potential cure because the genetic fix enabled by CRISPR is designed to last a lifetime, although confirmation will require years of follow-up.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： How to improve immunocompromised access to mAb treatments

WSS

Use wet bulb globe temperature, not heat index, to protect workers

Brain worms: The science behind RFK Jr.'s parasitic infection

Software glitch causes Tandem insulin pump to shutdown, FDA warns

Former Georgia lieutenant governor says he received grand jury subpoena

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

What nurses really want: sufficient staffing for patient care

entertainment

focus

hotspot

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Ohioans vote in high

Peter Hotez and the public health issue of online harassment

Sage's campaign to raise awareness of postpartum depression hits a nerve

United colonoscopy coverage change 'may cost lives,' doctors say

Use wet bulb globe temperature, not heat index, to protect workers

Cancer drug shortages should be causing more outrage

Wegovy cuts risk of cardiovascular events by 20%, study finds

New air purifier tech could be key to improving indoor air quality

Making AI in medicine accessible to smaller, and rural hospitals

focus

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Biden praises World Series champion Astros for impact off the field during White House celebration

The painfully weak evidence on taking collagen to treat arthritis

Former Georgia lieutenant governor says he received grand jury subpoena

What nurses really want: sufficient staffing for patient care

An Ebola outbreak presents a new mystery involving children

leisure time

explore

focus

Wikipedia